Clinical Trial Goal
To find out:
- The highest dose of tegavivint that’s safe to give
- If tegavivint is safe and works well to treat NHL that has relapsed or is refractory in children, teens and young adults
You may be able to join this trial if you:
- Are 1 – 30 years old
- Have NHL that has relapsed or is refractory. Some examples include:
- Burkitt lymphoma
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Mantle cell lymphoma (MCL)
- Marginal zone B-cell lymphoma
- Small lymphocytic lymphoma (SLL)
- Waldenström's macroglobulinaemia
- Other NHL
- Do not have untreated lymphoma in your brain or spinal cord
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 3 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Tegavivint is a small molecule inhibitor that blocks TBL1 in certain cells.
You’ll get:
You’ll get:
- Tegavivint – Given as intravenous (IV) infusions 1 time each week for the first 3 weeks of each month. Each infusion takes 4 hours. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for up to 2 years. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for as long as you're in the trial.
The Food and Drug Administration (FDA) has not yet approved tegavivint.
Locations
Sponsors
collaborator: National Cancer Institute (NCI), lead: Children's Oncology Group
